GSK/Innoviva’s Trelegy Ellipta wins expanded nod for COPD
US regulators have approved GlaxoSmithKline and Innoviva’s Trelegy Ellipta to treat a wider population of chronic obstructive pulmonary disease (COPD) patients.
Read More
Tag: vilanterol
GSK, Innoviva announce US nod for Trelegy Ellipta
GlaxoSmithKline and Innoviva have bagged a green light in the US for the novel triple therapy inhaler Trelegy Ellipta, opening the door to a new treatment option for patients with Chronic Obstructive Pulmonary Disorder (COPD).
Read More
GSK’s inhaler improves asthma control in ‘real world’ study
GlaxoSmithKline and Innoviva have unveiled data from a second ground-breaking Salford Lung Study (SLS) showing that Relvar Ellipta significantly improved asthma control versus patients’ standard therapy.
Read More
GSK files three-drug COPD inhaler in the US
GlaxoSmithKline and Innoviva have filed for approval in the US of a new once-daily, triple combination therapy for maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), some 18 months earlier than originally planned.
Read More
GSK’s Relvar Ellipta hits the mark in COPD trial
A “ground-breaking” UK study has shown that GlaxoSmithKline’s Relvar Ellipta is better than the standard of care in reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
